{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:40:34Z","timestamp":1792255234476,"version":"4.4.0"},"reference-count":27,"publisher":"Cambridge University Press (CUP)","issue":"9","license":[{"start":{"date-parts":[[2015,1,2]],"date-time":"2015-01-02T00:00:00Z","timestamp":1420156800000},"content-version":"unspecified","delay-in-days":2680,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infect. Control Hosp. Epidemiol."],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:sec id=\"S0195941700047299_abs1\"><jats:title>Objective.<\/jats:title><jats:p>Vancomycin-resistant enterococci (VRE) are a major cause of nosocomial infection. We sought to compare vancomycin-resistant (VR)<jats:italic>Enterococcus faecalis<\/jats:italic>bacteremia and VR<jats:italic>Enterococcus faecium<\/jats:italic>bacteremia in cancer patients with respect to risk factors, clinical presentation, microbiological characteristics, antimicrobial therapy, and outcomes.<\/jats:p><\/jats:sec><jats:sec id=\"S0195941700047299_abs2\"><jats:title>Methods.<\/jats:title><jats:p>We identified 210 cancer patients with VRE bacteremia who had been treated between January 1996 and December 2004; 16 of these 210 had VR<jats:italic>E. faecalis<\/jats:italic>bacteremia and were matched with 32 patients with VR<jats:italic>E. faecium<\/jats:italic>bacteremia and 32 control patients. A retrospective review of medical records was conducted.<\/jats:p><\/jats:sec><jats:sec id=\"S0195941700047299_abs3\"><jats:title>Results.<\/jats:title><jats:p>Logistic regression analysis showed that, compared with VR<jats:italic>E. faecalis<\/jats:italic>bacteremia, VR<jats:italic>E. faecium<\/jats:italic>bacteremia was associated with a worse clinical response to therapy (odds ratio [OR], 0.3 [95% confidence interval (CI), 0.07-0.98];<jats:italic>P<\/jats:italic>= .046) and a higher overall mortality rate (OR, 8.3 [95% CI, 1.9-35.3];<jats:italic>P<\/jats:italic>= .004), but the VRE-related mortality rate did not show a statistically significant difference (OR, 6.8 [95% CI, 0.7-61.8];<jats:italic>P<\/jats:italic>= .09). Compared with control patients, patients with VR<jats:italic>E. faecalis<\/jats:italic>bacteremia were more likely to have received an aminoglycoside in the 30 days before the onset of bacteremia (OR, 5.8 [95% CI, 1.2-27.6];<jats:italic>P<\/jats:italic>= .03), whereas patients with VR<jats:italic>E. faecium<\/jats:italic>bacteremia were more likely to have received a carbapenem in the 30 days before the onset of bacteremia (OR, 11.7 [95% CI, 3.6-38.6];<jats:italic>P<\/jats:italic>&lt;.001). In a multivariate model that compared patients with VR<jats:italic>E. faecium<\/jats:italic>bacteremia and control patients, predictors of mortality included acute renal failure on presentation (OR, 15.1 [95% CI, 2.3-99.2];<jats:italic>P<\/jats:italic>= .004) and VR<jats:italic>E. faecium<\/jats:italic>bacteremia (OR, 11 [95% CI, 2.7-45.1];<jats:italic>P<\/jats:italic>&lt;.001). No difference in outcomes was found between patients with VR<jats:italic>E. faecalis<\/jats:italic>bacteremia and control patients.<\/jats:p><\/jats:sec><jats:sec id=\"S0195941700047299_abs4\"><jats:title>Conclusions.<\/jats:title><jats:p>VR<jats:italic>E. faecium<\/jats:italic>bacteremia in cancer patients was associated with a poorer outcome than was VR<jats:italic>E. faecalis<\/jats:italic>bacteremia. Recent receipt of carbapenem therapy was an independent risk factor for VR<jats:italic>E. faecium<\/jats:italic>bacteremia, and recent receipt of aminoglycoside therapy was independent risk factor for<jats:italic>E. faecalis<\/jats:italic>bacteremia.<\/jats:p><\/jats:sec>","DOI":"10.1086\/519932","type":"journal-article","created":{"date-parts":[[2007,8,2]],"date-time":"2007-08-02T14:20:01Z","timestamp":1186064401000},"page":"1054-1059","source":"Crossref","is-referenced-by-count":64,"title":["Outcomes for and Risk Factors Associated With Vancomycin-Resistant<i>Enterococcus faecalis<\/i>and Vancomycin-Resistant<i>Enterococcus faecium<\/i>Bacteremia in Cancer Patients"],"prefix":"10.1017","volume":"28","author":[{"given":"G.","family":"Ghanem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. F.","family":"Chemaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Raad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2015,1,2]]},"reference":[{"key":"S0195941700047299_ref017","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.16.1905"},{"key":"S0195941700047299_ref021","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2005.08.015"},{"key":"S0195941700047299_ref001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198807213190307"},{"key":"S0195941700047299_ref026","first-page":"1271","article-title":"Uraemic toxic retention solutes depress polymorphonuclear response to phagocytosis","volume":"9","author":"Vanholder","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"S0195941700047299_ref018","doi-asserted-by":"publisher","DOI":"10.1089\/107662903322541928"},{"key":"S0195941700047299_ref013","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1007\/s00018-003-3138-0","article-title":"Pathogenic enterococci: new developments in the 21st century","volume":"60","author":"Tendolkar","year":"2003","journal-title":"Cell Mol Life Sci"},{"key":"S0195941700047299_ref009","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.6.1234"},{"key":"S0195941700047299_ref012","doi-asserted-by":"publisher","DOI":"10.1038\/nature00802"},{"key":"S0195941700047299_ref016","doi-asserted-by":"publisher","DOI":"10.1086\/503845"},{"key":"S0195941700047299_ref002","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.9.1588"},{"key":"S0195941700047299_ref003","doi-asserted-by":"publisher","DOI":"10.1067\/mic.2001.119952"},{"key":"S0195941700047299_ref004","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.19.2223"},{"key":"S0195941700047299_ref027","doi-asserted-by":"publisher","DOI":"10.3201\/1106.041204"},{"key":"S0195941700047299_ref005","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.04.007"},{"key":"S0195941700047299_ref006","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s100960100573","article-title":"Epidemiological analysis of vancomycin-resistant enterococci in a large tertiary-care hospital in Northern Italy","volume":"20","author":"Scagnelli","year":"2001","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"S0195941700047299_ref007","doi-asserted-by":"publisher","DOI":"10.1067\/mic.2000.106904"},{"key":"S0195941700047299_ref008","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1128\/AAC.43.10.2542","article-title":"The European VRE Study Group. Antimicrobial susceptibility patterns of enterococci causing infections in Europe","volume":"43","author":"Schouten","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"S0195941700047299_ref010","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.4.663"},{"key":"S0195941700047299_ref014","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-2-112"},{"key":"S0195941700047299_ref019","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00392-9"},{"key":"S0195941700047299_ref020","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.20.2461"},{"key":"S0195941700047299_ref011","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199206000-00025"},{"key":"S0195941700047299_ref022","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.2.296"},{"key":"S0195941700047299_ref023","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(94)00147-O"},{"key":"S0195941700047299_ref024","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.10.1528"},{"key":"S0195941700047299_ref025","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.7.4.462"},{"key":"S0195941700047299_ref015","doi-asserted-by":"publisher","DOI":"10.4065\/81.4.529"}],"container-title":["Infection Control &amp; Hospital Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0195941700047299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T15:22:32Z","timestamp":1587828152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0195941700047299\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S0195941700047299"],"URL":"https:\/\/doi.org\/10.1086\/519932","relation":{},"ISSN":["0899-823X","1559-6834"],"issn-type":[{"value":"0899-823X","type":"print"},{"value":"1559-6834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}